Record 2025 Revenue and New Cancer Data Deals Might Change The Case For Investing In Tempus AI (TEM)

Simply Wall St.01-13

In the past few days, Tempus AI reported preliminary 2025 results showing roughly US$1.27 billion in revenue with very large year-over-year growth, a record total contract value above US$1.10 billion,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603508504?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-01-13 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603508504","market":"sg","top_or_hot":-1,"title":"Record 2025 Revenue and New Cancer Data Deals Might Change The Case For Investing In Tempus AI (TEM)","media":"Simply Wall St.","content":"<div>\n<p>In the past few days, Tempus AI reported preliminary 2025 results showing roughly US$1.27 billion in revenue with very large year-over-year growth, a record total contract value above US$1.10 billion,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/record-2025-revenue-and-new-cancer-data-deals-might-change-t\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Record 2025 Revenue and New Cancer Data Deals Might Change The Case For Investing In Tempus AI (TEM)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecord 2025 Revenue and New Cancer Data Deals Might Change The Case For Investing In Tempus AI (TEM)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 11:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/record-2025-revenue-and-new-cancer-data-deals-might-change-t><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the past few days, Tempus AI reported preliminary 2025 results showing roughly US$1.27 billion in revenue with very large year-over-year growth, a record total contract value above US$1.10 billion,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/record-2025-revenue-and-new-cancer-data-deals-might-change-t\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/record-2025-revenue-and-new-cancer-data-deals-might-change-t","article_id":"2603508504","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/record-2025-revenue-and-new-cancer-data-deals-might-change-t","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603508504","pubTimestamp":1768274578,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In the past few days, Tempus AI reported preliminary 2025 results showing roughly US$1.27 billion in revenue with very large year-over-year growth, a record total contract value above US$1.10 billion, and more than 70 data agreements alongside new oncology collaborations with NYU Langone Health and Northwestern Medicine.\nTogether, these updates point to a company deepening its role at the intersection of genomic testing, longitudinal cancer data, and AI-powered decision support for both...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK7095":"多种金属与采矿","BK4543":"AI","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念","BK4528":"SaaS概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4613":"AI应用软件","TEM":"Tempus AI","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4023":"应用软件","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4611":"AI医疗"},"translate_title":"2025年创纪录的收入和新的癌症数据交易可能会改变投资Tempus AI(TEM)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1.98},"content_text":"In the past few days, Tempus AI reported preliminary 2025 results showing roughly US$1.27 billion in revenue with very large year-over-year growth, a record total contract value above US$1.10 billion, and more than 70 data agreements alongside new oncology collaborations with NYU Langone Health and Northwestern Medicine. Together, these updates point to a company deepening its role at the intersection of genomic testing, longitudinal cancer data, and AI-powered decision support for both health systems and drugmakers. Next, we’ll examine how this record total contract value and major academic cancer-center partnerships may influence Tempus AI’s existing investment narrative. These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.AdvertisementTempus AI Investment Narrative RecapTo own Tempus AI, you need to believe that its AI and genomics platform can become a core part of how cancer is diagnosed and treated, and that growing pharma and health system demand can eventually support a path toward sustainable cash generation. The latest results and contract wins bolster the near term revenue growth catalyst, but they do not resolve the key risk that heavy investment and pricing pressure in a competitive genomics and AI market could delay meaningful profitability. Among the latest updates, the multi year collaboration with NYU Langone Health stands out because it ties Tempus directly into a large, longitudinal cancer study, reinforcing its pitch that richer real world genomic datasets can support more valuable AI tools for drugmakers. That kind of academic anchor relationship may help the company deepen its data licensing opportunities, which has been a core short term growth driver alongside diagnostics volume. Yet while the business is scaling quickly, investors should also be aware that intensifying competition and ongoing reimbursement uncertainty could... Read the full narrative on Tempus AI (it's free!)Tempus AI's narrative projects $2.1 billion revenue and $295.0 million earnings by 2028.Uncover how Tempus AI's forecasts yield a $87.92 fair value, a 27% upside to its current price.Exploring Other PerspectivesTEM 1-Year Stock Price Chart Simply Wall St Community members have 32 fair value estimates for Tempus AI, ranging from US$25.24 to US$183.10 per share. When you weigh those views against the company’s heavy ongoing R&D and capex needs, it underlines why many participants are watching execution and cash burn very closely.Explore 32 other fair value estimates on Tempus AI - why the stock might be worth less than half the current price!Build Your Own Tempus AI NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Tempus AI research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.Contemplating Other Strategies?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Rare earth metals are the new gold rush. Find out which 39 stocks are leading the charge.AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tempus AI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603508504","isCrawlerRequest":true}